Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hDNAgr Technology for Aging
NCT06877377Phase 1Not yet recruiting
- Sponsor
- S-LAB
- Start
- Sep 2025
- Primary completion
- Feb 2026
01
Overview
Phase 1, randomised, double-blind trial in aging (2 arms), sponsored by S-LAB. Primary endpoint: Incidence of Any Treatment-Emergent Adverse Events at 180 days. Planned start Sep 2025; status: not yet recruiting.
02
Conditions
aging
Beyond the preview
Go deeper on NCT06877377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06877377.